LBL, Good to see you back posting here! No doubt AD has a game plan and I hope it pans out as he envisions. Hard to believe AMRN management would treat AD as horribly as they have, then again, why should they treat him any different than they have anything else AMRN related. My hope is that Denner is working with Dr. Bhatt who is on the BOD of Bristol-Myers Squibb. I'm certain that Bhatt does not want to see his "baby" laid to waste. Amarin desperately needs a BP to market & distribute Vazkepa competently across Europe & the ROW. Maybe a BP could eventually help out Eddingpharm in due time. KM seems to want to follow in JT's footsteps to be a failure at building a BP.
Market Data 
Markets 
AI
